Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab Dose Optimization
2024-519207-10-00Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Percentage change in LDH between standard dosing and individualized dosing and Target ravulizumab concentration attainment. Planned start Feb 2025; status: authorised.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2024-519207-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519207-10-00.